尼拉帕利对比铂-紫杉醇双药化疗作为新诊断HRd晚期卵巢癌新辅助治疗:OPAL 2期试验C队列结果
OPAL 1b/2期试验C队列将36例新诊断III/IV期同源重组缺陷(HRd)晚期卵巢癌患者1:1随机分配至新辅助尼拉帕利或铂-紫杉醇化疗。新辅助期尼拉帕利组术前未确认客观缓解率(ORR)为31.6%,铂-紫杉醇组为70.6%,差异-39.0%(80%CI -56.8%至-17.7%),试验因无效提前终止。
要点
- 新辅助尼拉帕利组术前未确认ORR为31.6%,低于铂-紫杉醇组的70.6%。
- ORR差异为-39.0%(80%CI -56.8%至-17.7%),支持铂-紫杉醇。
- 试验因无效提前终止;两组新辅助期≥3级不良事件率分别为42%和59%。
核心结论
- 在新诊断HRd晚期卵巢癌中,新辅助尼拉帕利较标准铂类化疗未改善ORR,试验提前终止。
研究设计与样本
- OPAL 1b/2期试验C队列,随机1:1分配36例新诊断III/IV期HRd晚期卵巢癌患者,19例接受尼拉帕利、17例接受铂-紫杉醇。
- 预筛选期患者接受1个导入周期卡铂-紫杉醇;新辅助治疗后达未确认完全/部分缓解或疾病稳定者可接受间歇性减瘤术,术后接受辅助铂-紫杉醇化疗,无进展者接受尼拉帕利维持治疗。
- 主要终点为术前未确认的研究者评估ORR(RECIST标准),次要终点包括安全性。
主要发现
- 术前未确认ORR在尼拉帕利组为31.6%(CR/PR 0/31.6%),铂-紫杉醇组为70.6%(CR/PR 0/70.6%)。
- 术前未确认ORR差异为-39.0%(80%CI -56.8%至-17.7%),支持铂-紫杉醇。
- 新辅助期≥3级不良事件率在尼拉帕利组为42%、铂-紫杉醇组为59%,未发生致命性严重不良事件。
关键数值与推荐
- 术前未确认ORR差异-39.0%(80%CI -56.8%至-17.7%),支持铂-紫杉醇。
- 新辅助期≥3级不良事件率:尼拉帕利组42%,铂-紫杉醇组59%。
临床怎么用
- 对于新诊断HRd晚期卵巢癌,不推荐以尼拉帕利替代铂-紫杉醇作为新辅助治疗。
局限性
- 样本量小(共36例),试验因无效提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite therapeutic improvements in advanced ovarian cancer (aOC), prognosis remains poor for patients with residual disease after cytoreductive surgery. Reported here are results from cohort C of the phase 1b/2 OPAL study of a neoadjuvant poly(ADP-ribose) polymerase (PARP) inhibitor for aOC. METHODS: Eligible adults with newly diagnosed stage III/IV homologous recombination-deficient (HRd) aOC and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 were randomized 1:1 to receive neoadjuvant platinum-taxane chemotherapy (platinum-taxane) or niraparib. During the prescreening period, patients received 1 run-in cycle of carboplatin-paclitaxel. After neoadjuvant therapy, patients with an unconfirmed complete/partial response (CR/PR) or stable disease per RECIST could undergo interval debulking surgery (IDS), followed by adjuvant platinum-taxane-based chemotherapy. After adjuvant therapy, patients without progression received niraparib-based maintenance treatment. Primary endpoint was pre-IDS unconfirmed investigator-assessed overall response rate (ORR) per RECIST. Secondary endpoints included safety. RESULTS: Of 36 patients randomized, 19 received niraparib and 17, platinum-taxane. Baseline demographics and characteristics were similar between arms. Overall, the pre-IDS unconfirmed ORR was 31.6% (CR/PR, 0/31.6%) with niraparib and 70.6% (CR/PR, 0/70.6%) with platinum-taxane. The pre-IDS unconfirmed ORR (80% CI) difference was -39.0% (-56.8% to -17.7%), favoring platinum-taxane. The trial was closed early for futility. Grade ≥3 adverse-event rates during the neoadjuvant period were 42% and 59% in the niraparib and platinum-taxane arms, respectively. No fatal serious adverse events occurred. CONCLUSIONS: In newly diagnosed HRd aOC, neoadjuvant niraparib did not improve ORR versus standard platinum-based chemotherapy, and the trial was discontinued. The safety profile was consistent with those of previous PARP inhibitor studies.
引用
- Westin SN, Belotte J, Felicetti B, et al. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial. Gynecol Oncol. 2026. PMID: 42623963. doi:10.1016/j.ygyno.2026.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。